IMVT

Immunovant (IMVT)

About Immunovant (IMVT)

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Details

Daily high

$23.65

Daily low

$22.33

Price at open

$22.66

52 Week High

$29.22

52 Week Low

$12.72

Market cap

4.0B

Dividend yield

0.00%

Volume

1.1M

Avg. volume

1.2M

P/E ratio

-8.04

Immunovant News